| Diabetes Mellitus
Rezgovlar vs Afrezza - (Insulin Human) Inhalation Powder
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Rezvoglar vs Afrezza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAfrezza has a higher rate of injection site reactions vs Rezvoglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Afrezza but not Rezvoglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezvoglar
Afrezza
At A Glance
SC injection
Once daily
Long-acting insulin analog
Oral inhalation
At each meal
Rapid-acting insulin
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time every day; use short-acting premeal insulin for the remainder.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily in insulin-naive patients, adjusted based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus Insulin-naive patients: 4 units inhaled at the beginning of each meal; patients switching from subcutaneous mealtime insulin convert per table (up to 3 units -> 4 units, 4-5 units -> 8 units, 6-7 units -> 12 units, >=8 units -> 16 units); adjust dose based on metabolic needs, blood glucose monitoring, and glycemic control goal.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in REZVOGLAR
- Episodes of hypoglycemia
- Chronic lung disease such as asthma or COPD due to risk of acute bronchospasm
- Previous severe hypersensitivity reaction to any regular human insulin product or any inactive ingredient in AFREZZA
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache, retinal vascular disorder
Serious Severe hypoglycemia, anaphylaxis, angioedema, bronchospasm, hypotension, shock, hypokalemia, lipodystrophy
Postmarketing Localized cutaneous amyloidosis, medication errors with inadvertent insulin substitution, hyperglycemia or hypoglycemia related to injections into amyloidosis-affected sites
Most common (>=2%) Cough, throat pain or irritation, headache, diarrhea, productive cough, fatigue, nausea
Serious Acute bronchospasm, hypoglycemia, decline in pulmonary function, lung cancer, diabetic ketoacidosis, hypersensitivity reactions
Postmarketing Bronchospasm
Pharmacology
Long-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, lipolysis, and proteolysis while enhancing protein synthesis.
Insulin lowers blood glucose in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; it also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezvoglar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Afrezza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Rezvoglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (2/8)
Afrezza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rezvoglar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Afrezza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rezvoglar.
$99/momo
Afrezza Patient Direct ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezvoglarView full Rezvoglar profile
AfrezzaView full Afrezza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.